- -

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy

Mostrar el registro sencillo del ítem

Ficheros en el ítem

dc.contributor.author Garrido-Cano, Iris es_ES
dc.contributor.author Adam-Artigues, Anna es_ES
dc.contributor.author Lameirinhas, Ana es_ES
dc.contributor.author Blandez, Juan F. es_ES
dc.contributor.author Candela-Noguera, Vicente es_ES
dc.contributor.author Lluch, Ana es_ES
dc.contributor.author Bermejo, Begoña es_ES
dc.contributor.author Sancenón Galarza, Félix es_ES
dc.contributor.author Cejalvo, Juan Miguel es_ES
dc.contributor.author Martínez-Máñez, Ramón es_ES
dc.contributor.author Eroles, Pilar es_ES
dc.date.accessioned 2024-04-11T11:58:38Z
dc.date.available 2024-04-11T11:58:38Z
dc.date.issued 2023-08 es_ES
dc.identifier.issn 1944-8244 es_ES
dc.identifier.uri http://hdl.handle.net/10251/203426
dc.description.abstract [EN] Despite advancesin breast cancer treatment, it remainsthe leadingcause of cancer-related death in women worldwide. In this context,microRNAs have emerged as potential therapeutic targets but stillpresent some limitations for in vivo applications.Particularly, miR-200c-3p is a well-known tumor suppressor microRNAthat inhibits tumor progression and metastasis in breast cancer throughdownregulating ZEB1 and ZEB2. Basedon the above, we describe the design and validation of a nanodeviceusing mesoporous silica nanoparticles for miR-200c-3p delivery forbreast cancer treatment. We demonstrate the biocompatibility of thesynthesized nanodevices as well as their ability to escape from endosomes/lysosomesand inhibit tumorigenesis, invasion, migration, and proliferationof tumor cells in vitro. Moreover, tumor targetingand effective delivery of miR-200c-3p from the nanoparticles in vivo are confirmed in an orthotopic breast cancer mousemodel, and the therapeutic efficacy is also evidenced by a decreasein tumor size and lung metastasis, while showing no signs of toxicity.Overall, our results provide evidence that miR-200c-3p-loaded nanoparticlesare a potential strategy for breast cancer therapy and a safe andeffective system for tumor-targeted delivery of microRNAs. es_ES
dc.description.sponsorship This research was supported by project PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/ and by European Regional Development Fund A way of doing Europe. Also, this study forms part of the Advanced Materials program (MFA/2022/049) and was supported by MCIN with funding from European Union NextGeneration EU(PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was also supported by CIBER Consorcio Centro de Investigación Biomédica en Red CIBER-BBN(CB07/01/2012), CIBERONC(CB16/12/00481), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. This work was also supported by Spanish Government and cofinanced by FEDER Funds (PI18/01219, PI21/01351) .I.G.-C. was funded by Margarita Salas post doctoral grant (European Union-Nextgeneration EU). A.A.-A. and A.L. were funded by Asociación Española Contra el Cancer.J.F.B. was funded by Instituto de Salud Carlos III and the European Social Fund for the financial support 'Sara Borrell' (CD19/00038). V.C.-N. was funded by Ministerio de Ciencia e Innovacio¿n (FPU grant), and J.M.C. was funded by Sociedad Española de Oncología Médica (Río Hortega-SEOM) es_ES
dc.language Inglés es_ES
dc.publisher American Chemical Society es_ES
dc.relation.ispartof ACS Applied Materials & Interfaces es_ES
dc.rights Reconocimiento (by) es_ES
dc.subject Mesoporous silica nanoparticles es_ES
dc.subject Breast cancer es_ES
dc.subject MicroRNA es_ES
dc.subject Therapy es_ES
dc.subject Targeted delivery es_ES
dc.subject.classification QUIMICA ORGANICA es_ES
dc.subject.classification QUIMICA INORGANICA es_ES
dc.title Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy es_ES
dc.type Artículo es_ES
dc.identifier.doi 10.1021/acsami.3c07541 es_ES
dc.relation.projectID info:eu-repo/grantAgreement/AEI/Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023/PID2021-126304OB-C41/ES/NUEVOS MATERIALES Y SONDAS PARA EL RECONOCIMIENTO, LIBERACION DE FARMACOS, NANOMOTORES Y COMUNICACION/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/GVA//MFA%2F2022%2F049/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/GVA//CIPROM%2F2021%2F007/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/ISCIII//CD19%2F00038/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/ISCIII//PI21%2F01351/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/ISCIII//PI18%2F01219/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MINECO//CB16%2F12%2F00481//CANCER/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MICINN//PRTR-C17.I1/ es_ES
dc.relation.projectID info:eu-repo/grantAgreement/MICINN//CB07%2F01%2F2012//Bioingeniería, biomateriales y nanomedicina/ es_ES
dc.rights.accessRights Abierto es_ES
dc.contributor.affiliation Universitat Politècnica de València. Escuela Técnica Superior de Ingenieros Industriales - Escola Tècnica Superior d'Enginyers Industrials es_ES
dc.description.bibliographicCitation Garrido-Cano, I.; Adam-Artigues, A.; Lameirinhas, A.; Blandez, JF.; Candela-Noguera, V.; Lluch, A.; Bermejo, B.... (2023). Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy. ACS Applied Materials & Interfaces. 15(32):38323-38334. https://doi.org/10.1021/acsami.3c07541 es_ES
dc.description.accrualMethod S es_ES
dc.relation.publisherversion https://doi.org/10.1021/acsami.3c07541 es_ES
dc.description.upvformatpinicio 38323 es_ES
dc.description.upvformatpfin 38334 es_ES
dc.type.version info:eu-repo/semantics/publishedVersion es_ES
dc.description.volume 15 es_ES
dc.description.issue 32 es_ES
dc.identifier.pmid 37549382 es_ES
dc.identifier.pmcid PMC10436244 es_ES
dc.relation.pasarela S\508702 es_ES
dc.contributor.funder European Commission es_ES
dc.contributor.funder Generalitat Valenciana es_ES
dc.contributor.funder Instituto de Salud Carlos III es_ES
dc.contributor.funder Agencia Estatal de Investigación es_ES
dc.contributor.funder European Regional Development Fund es_ES
dc.contributor.funder Ministerio de Ciencia e Innovación es_ES
dc.contributor.funder Universitat Politècnica de València es_ES
dc.contributor.funder Ministerio de Economía y Competitividad es_ES
dc.contributor.funder Sociedad Española de Oncología Médica es_ES


Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem